Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neurizon Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
In big news week Neurizon secures key orphan status for motor neurone drug in Europe
Health & Biotech
Neurizon files key IND application with US FDA for motor neurone disease drug
Health & Biotech
Health Check: It’s a wipe out! Percheron shares tumble up to 91pc on rare genetic disease trial failure
Health & Biotech
Positive interim study results for Neurizon’s motor neurone disease drug
Health & Biotech
Health Check: Can Syntara produce the next multibillion-dollar Aussie blood cancer drug?
Health & Biotech
Preclinical studies confirm potential of Neurizon’s lead drug to treat ALS
Health & Biotech
Scott Power: S&P/ASX 200 Health Care Index falls but which stocks are up on positive news?
Health & Biotech
NUZ inks positive opinion on orphan product designation for NUZ-001 in Europe
Health & Biotech
Spark Plus sees 225pc upside in biotech player Neurizon
Health & Biotech
Neurizon’s strong September quarter to propel treatments for neurodegenerative diseases forward
Stockhead TV
Long Shortz with Neurizon Therapeutics: Goodbye to PharmAust, hello to neuro horizons
Health & Biotech
PharmAust rebrands as Neurizon Therapeutics as it pioneers treatment for neurodegenerative diseases
Health & Biotech
Dr Boreham’s Crucible: Can this small company meet MND drug development’s sizeable need?
News
Closing Bell: ASX up but MinRes slumps on lithium downgrade; China stocks also sink
Stockhead TV
Long Shortz with PharmAust: Sweet incentives for sad disease’s drug development
Health & Biotech
Health Kick Podcast: PharmAust in the fight against MND and ALS with lead drug monepantel
